Introgen announces patent for adenoviral p53 manufacturing methods

New York, April 26 - Introgen Therapeutics, Inc. said the U.S. Patent and Trademark Office has awarded a patent that broadly covers methods used to produce adenoviral p53.

The Austin, Texas-based biopharmaceutical company said the patent expands its adenoviral p53 portfolio and protection for its lead cancer therapy, Advexin.

The patent is one of many that Introgen has licensed exclusively from the Board of Regents of The University of Texas System.

Introgen's Advexin therapy uses non-replicating adenovirus, an important and frequently used tool in the fields of tumor suppressor therapy and vaccines.

"This patent is of particular importance in that it is directed to the production of adenoviral p53 in producer cells, and complements our existing U.S. portfolio, which includes patents directed to pharmaceutical compositions of adenoviral p53, the adenoviral p53 itself and to clinical applications of adenoviral p53," said David L. Parker, vice president of intellectual property for Introgen, in a news release.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.